Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.
Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Phytother Res. 2019 Oct;33(10):2609-2621. doi: 10.1002/ptr.6441. Epub 2019 Jul 29.
The aim of this systematic review and meta-analysis was to evaluate the effects of spirulina on glycemic control and serum lipoproteins in patients with metabolic syndrome (MetS) and related disorders. Two independent authors systematically searched online database including EMBASE, Scopus, PubMed, Cochrane Library, and Web of Science from inception until April 30, 2019. The Cochrane Collaboration's risk of bias tool was applied to assess the methodological quality of included trials. The heterogeneity among the included studies was assessed using Cochrane's Q test and I-square (I ) statistic. Pooling effect sizes from studies showed a significant reduction in fasting plasma glucose (FPG; weighted mean difference [WMD]: -10.31; 95% confidence interval, CI [-16.21, -4.42]) and insulin concentrations (WMD: -0.53; 95% CI [-0.62, -0.44]) following the administration of spirulina. Pooled analysis showed also a significant reduction in total cholesterol (WMD: -20.50; 95% CI [-38.25, -2.74]), low-density lipoprotein cholesterol (LDL-C; WMD: -19.02; 95% CI [-36.27, -1.78]), and very low-density lipoprotein cholesterol (VLDL-C) concentrations (WMD: -6.72; 95% CI [-9.19, -4.26]) and a significant increase in high-density lipoprotein cholesterol (HDL-C) levels (WMD: 1.42; 95% CI [0.16, 2.68]) following spirulina therapy. This meta-analysis demonstrated the beneficial effects of spirulina supplementation on improving FPG, insulin, total cholesterol, LDL-C, VLDL-C, and HDL-C levels in patients with MetS and related disorders.
本系统评价和荟萃分析的目的是评估螺旋藻对代谢综合征（MetS）及相关疾病患者血糖控制和血清脂蛋白的影响。两位独立作者系统地检索了在线数据库，包括 EMBASE、Scopus、PubMed、Cochrane 图书馆和 Web of Science，检索时间从建库至 2019 年 4 月 30 日。采用 Cochrane 协作风险偏倚工具评估纳入试验的方法学质量。采用 Cochrane's Q 检验和 I 平方（I ）统计量评估纳入研究的异质性。对研究进行合并效应量分析显示，螺旋藻治疗后空腹血糖（FPG；加权均数差 [WMD]：-10.31；95%置信区间 [CI]：[-16.21，-4.42]）和胰岛素浓度（WMD：-0.53；95% CI：[-0.62，-0.44]）显著降低。荟萃分析还显示，总胆固醇（WMD：-20.50；95% CI：[-38.25，-2.74]）、低密度脂蛋白胆固醇（LDL-C；WMD：-19.02；95% CI：[-36.27，-1.78]）和极低密度脂蛋白胆固醇（VLDL-C）浓度（WMD：-6.72；95% CI：[-9.19，-4.26]）显著降低，高密度脂蛋白胆固醇（HDL-C）水平（WMD：1.42；95% CI：[0.16，2.68]）显著升高。本荟萃分析表明，螺旋藻补充剂对改善 MetS 及相关疾病患者的 FPG、胰岛素、总胆固醇、LDL-C、VLDL-C 和 HDL-C 水平具有有益作用。
